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Manipulation of PBF/PTTG1IP Phosphorylation Status;
a Potential New Therapeutic Strategy for Improving
Radioiodine Uptake in Thyroid and Other Tumors
V. E. Smith,* N. Sharma,* R. J. Watkins, M. L. Read, G. A. Ryan, P. P. Kwan,
A. Martin, J. C. Watkinson, K. Boelaert, J. A. Franklyn, and C. J. McCabe
School of Clinical and Experimental Medicine (V.E.S., N.S., R.J.W., M.L.R., G.A.R., P.P.K., J.C.W., K.B.,
J.A.F., C.J.M.), Institute of Biomedical Research, and School of Cancer Sciences (A.M.), University of
Birmingham, Birmingham B15 2TT, United Kingdom
Context: The clinical effectiveness of ablative radioiodine treatment of thyroid tumors is limited
by the availability of the sodium iodide symporter (NIS) at the plasma membrane (PM) for uptake
of 131I. A significant proportion of well-differentiated thyroid tumors are unable to concentrate
sufficient radioiodine for effective therapy, and in other tumor models such as breast tumors,
where radioiodine uptake would be an attractive therapeutic option, uptake is insufficient.
Objective: Pituitary tumor–transforming gene-binding factor (PBF; PTTG1IP) is overexpressed in
multiple cancers and significantly decreases NIS expression at the PM. The goal of this study was
to identify a method by which PBF repression of NIS may be overcome in human tumors.
Results: Here, we identify PBF as a tyrosine phosphoprotein that specifically binds the proto-
oncogene tyrosine protein kinase Src in mass spectrometry, glutathione S-transferase pulldown
and coimmunoprecipitation assays. Src induction leads to phosphorylation at PBF residue Y174.
Abrogation of this residue results in PM retention and amarkedly reduced ability to bind NIS. The
Src inhibitor PP1 inhibits PBF phosphorylation in multiple cell lines in vitro, including human pri-
mary thyroid cells. Of direct clinical importance to the treatment of thyroid cancer, PP1 stimulates
iodide uptake by transfected NIS in TPC1 thyroid carcinoma cells and entirely overcomes PBF
repression of iodide uptake in human primary thyroid cells.
Conclusions:We propose that targeting PBF phosphorylation at residue Y174 via tyrosine kinase
inhibitors may be a novel therapeutic strategy to enhance the efficacy of ablative radioiodine
treatment in thyroid and other endocrine and endocrine-related tumors. (J Clin EndocrinolMetab
98: 2876–2886, 2013)
Radioiodine is a safe and effective modality used formore than60years in the treatmentof thyroid cancer
and has potential uses in breast, prostate, and other can-
cers. Ablative radioiodine therapy exploits the ability of
the thyroid to take up iodide, a process mediated by the
sodium iodide symporter (NIS), which transports iodide
across the basolateral plasma membrane (PM) of thyroid
follicular epithelial cells for thyroid hormone biosynthesis
(1, 2). Many thyroid cancers demonstrate reduced NIS
activity through diminished expression (3) and intracel-
lular retention (4–6). TSH can induce both NIS expres-
sion and cell surface targeting, and TSH stimulation is
required to successfully induce iodide uptake inmostwell-
differentiated thyroid tumors. However, up to 20% of
these tumors fail to concentrate enough radioiodine for
effective therapy, even after TSH stimulation (3). Further,
dedifferentiated and metastatic thyroid tumors generally
respond poorly to radioiodine therapy. Hence, tumors
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with reduced NIS activity are commonly associated with
a poor prognosis.More broadly, whereas the endogenous
NIS expression demonstrated in breast tumors can facil-
itate radioiodine uptake (6, 7) andmultiple tumors can be
engineered to do so, uptake in these cancers is currently
inadequate for effective therapeutic efficacy (8).
Also known as PTTG1IP or c21orf3 (9), pituitary tu-
mor–transforming gene-binding factor (PBF) is trans-
forming in vitro, is tumorigenic in vivo (10), and is induced
in breast tumors (11). In thyroid cancer, PBF is signifi-
cantly up-regulated, and higher PBF expression is inde-
pendently associated with early tumor recurrence and an
overall poorer disease outcome (10, 12, 13).We have pre-
viously implicated PBF in 2 discrete mechanisms of NIS
repression (14–16). PBF overexpression has been demon-
strated to repress NIS expression both in vitro and in vivo
(14, 16). Further, PBF binds to NIS and reduces iodide
uptake through modulation of its subcellular localization
(15). In addition, the thyroidhormone transporterMCT8,
which mediates the secretion of thyroid hormone, was
recently found tobe similarly regulatedbyPBF, suggesting
that PBF may be a key regulator in thyroid hormone bio-
synthesis and secretion (17). Indeed, thyroid-specific PBF
overexpression in the mouse resulted in gross thyroid
gland enlargement, hyperplasia, macrofollicular lesions,
and, significantly, a greatly impaired ability for uptake of
radioiodine (16). PBF is, thus, a protein that is dysregu-
lated in thyroid tumorigenesis and that elicits potent re-
pression of NIS function.
Understanding the factors repressing NIS activity is
critical in improving radioiodine delivery to tumors that
are unable to take up radioiodine effectively. Intensive
interest therefore exists in identifying mechanisms of up-
regulating endogenous NIS expression through the use of
histone deacetylase inhibitors, demethylating agents, nu-
clear receptor agonists, and kinase inhibitors and in tu-
mor-targeted NIS gene therapy (18). However, our data
suggest that if PBF is overexpressed in a tumor, induction
of NIS expression alone may be insufficient, given the
posttranslational repression of NIS by PBF (15). Thus, a
therapeutic strategy targeting PBF would also be needed
for increased clinical effectiveness.
In the current investigation, we have extended our
initial observation that PBF overexpression can post-
translationally repress NIS in normal thyroid cells by
demonstrating NIS and PBF colocalization within the
intracellular vesicles of multiple human tumor cell lines.
These included papillary and anaplastic thyroid, breast,
and prostate cancer cells. We have determined that PBF is
phosphorylated at tyrosine 174 (Y174), a residue we have
found to be important in the regulation of PBF endocyto-
sis. PBF bound to the tyrosine kinase Src, with induced Src
expression, resulting in increased PBF Y174 phosphory-
lation. Conversely, the Src inhibitor PP1 reduced pY174
levels in multiple cell lines and in human primary thyroid
cells. Abrogation of Y174 significantly diminished the in-
teraction between PBF and NIS, and pY174 PBF colocal-
ized with NIS. Critically, treatment with PP1 overcame
PBF repression of iodide uptake into human primary
thyroid cells. We suggest therefore that targeting PBF
phosphorylation may have a significant impact on the
efficacy of radioiodine treatment of thyroid and other
tumors, where uptake is currently insufficient for effec-
tive ablation.
Materials and Methods
Cell lines and human primary thyroid culture
COS-7African greenmonkey kidney epithelial, HeLa human
cervical carcinoma, and T47D human breast cancer cell lines
were maintained in DMEM, high glucose (PAA, Pasching, Aus-
tria). TPC1, K1, and SW1736 thyroid carcinoma, Saos-2 osteo-
sarcoma,LNCaPprostate cancer, andA2780ovarian carcinoma
cell lines were maintained in RPMI 1640 medium (Life Tech-
nologies, Inc, Paisley, Scotland, United Kingdom). VCaP pros-
tate cancer and HCT166 colorectal carcinoma cell lines were
maintained in DMEM/F-12 andMcCoy’s 5A media (Life Tech-
nologies, Inc), respectively. All were supplemented with 10%
fetal bovine serum (FBS), penicillin (105 U/L), and streptomycin
(100 mg/L).
Collection of thyroid samples was in accordance with ap-
proval of the local research ethics committee, and subjects gave
informed written consent. Preparation of human thyroid follic-
ular cells from surgical specimens was based on a method de-
scribedpreviously (19). Inbrief, thyroid tissuewasdigestedusing
0.2% collagenase (Worthington Biochemical Corp, Lakewood,
New Jersey). Follicles were plated in medium described by
Ambesi-Impiombato et al (20), supplemented with TSH (300
mU/L), insulin (300 g/L), penicillin (105 U/L), streptomycin
(100 mg/L), and 4% FBS. After 72 hours, FBS was omitted, and
experiments were performed 11 days later.
Plasmids and transfection
Plasmids containing the full-length PBF cDNA with a hemag-
glutinin (HA) tag and NIS cDNA with a MYC tag have been
described previously (10, 15). Mutants Y174A and F177A were
created by mutating the PBF-HA plasmid using a QuikChange
Site-Directed Mutagenesis Kit (Stratagene, Cambridge, United
Kingdom) with the primers 5-CCTGTTTAAAGAAGAAAAC-
CCGGCTGCTAGATTTGAAAACAACTAC-3 and 5-GAA
AACCCGTATGCTAGAGCTGAAAACAACTACCCATACG-
3, respectively. Nucleotide substitutions are underlined. Full-
length Src cDNA (kindly donated by Dr. Yotis Senis, University of
Birmingham, Birmingham, United Kingdom) was subcloned into
pcDNA3.1 (Life Technologies, Inc) using the EcoR1 and Xba1
restriction sites.
Cells were transfected using FuGENE 6 reagent (Roche, In-
dianapolis, Indiana), following the manufacturer’s instructions
at a 3:1 reagent to DNA ratio.
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Antibodies and reagents
The following antibodies were used:mousemonoclonal anti-
HA.11 antibody (Covance Research Products, Princeton, New
Jersey), rabbit polyclonal anti-HA (Y-11) antibody (Santa Cruz
Biotechnology, Santa Cruz, California), PBF phospho-specific
antibody to residue Y174 (CovalAb, Villeurbanne, France),
mouse monoclonal anti-Myc-Tag (9B11) antibody (Cell Signal-
ing Technology, Danvers, Massachusetts), rabbit anti-Src
(36D10) antibody (Cell Signaling Technology), rabbit poly-
clonal anti-PBF antibody (made by Eurogentec [Seraing, Bel-
gium] for our laboratory using the full-length PBF protein as an
epitope), rabbit polyclonal anti-NIS antibody (ab104920; Ab-
cam, Cambridge, United Kingdom), and mouse monoclonal an-
ti–-actin antibody (clone AC-15; Sigma, Poole, Dorset, United
Kingdom). The Src kinase inhibitor PP1 and the negative control
compound PP3 were kind gifts from Dr Yotis Senis.
Immunofluorescence staining
Immunofluorescence staining was performed as described
previously (15). For detection of pY174, cellswere treated for 15
minutes with pervanadate (100 M) before fixation.
Epifluorescent microscopy was performed using 40 and
100 objectives on a Zeiss Axioplan fluorescent microscope
(Zeiss, Oberkochen, Germany). A Zeiss confocal LSM 510 mi-
croscope with 63 and 100 objectives was used to perform
confocal microscopy.
Western analysis
Westernblottingwasperformed throughout asdescribedpre-
viously (17). For assessment of pY174 expression, cells were
treated for 15 minutes with pervanadate (100 M) before lysis
in a modified radioimmunoprecipitation assay buffer (50 mM
Tris-HCl [pH 7.4], 150 mM NaCl, 1% vol/vol Igepal CA-630,
6 mM sodium deoxycholate, and 1 mMEGTA) containing pro-
tease inhibitor cocktail (Sigma) and 1 mM sodium orthovana-
date (Sigma). PBF-HA or -actin expression was assessed to de-
termine total PBF expression and/or act as a loading control
where appropriate.
Cell surface biotinylation
PBF-HA, Y174A, and F177A plasmids (2 g) were trans-
fected intoCOS-7 cells in 6-well plates.Cell surfacebiotinylation
assays were performed as described previously (17). Wild-type
and mutant PBF were subsequently detected in both membrane
protein andwhole-cell lysate fractions byWestern analysis using
mouse anti-HA.11 antibody (Covance Research Products).
Immunoprecipitation/coimmunoprecipitation
assays
All transfections for these assays were performed in T25
flasks using 5g ofDNA. Immunoprecipitation (IP) assayswere
performed as described previously (17).
To determine specific binding of the pY174 antibody,
PBF-HA and Y174A were transfected into COS-7 and K1 cells
and immunoprecipitated from lysate treated for 15minuteswith
pervanadate (100 M) before being harvested with mouse anti-
HA.11 antibody (Covance Research Products). Phosphorylated
PBF was detected after Western blotting and probing with the
phospho-specific pY174 antibody.
To assess a possible interaction between PBF and Src, HeLa
cells were transfected with PBF-HA and vector only (VO) con-
trol, PBF-HA and Src, and VO and Src. After IP of PBF-HAwith
mouse anti-HA.11 antibody (Covance Research Products), the
coimmunoprecipitation of exogenous Src was determined by
Western blotting and probing with rabbit anti-Src (36D10) an-
tibody (Cell Signaling Technology). The reciprocal assay was
also performed.
To assess the effect of the PBF mutation on binding to NIS,
coimmunoprecipitation assayswere performed as described pre-
viously with lysate fromCOS-7 cells transfected withNIS-MYC
and either VO, PBF-HA, or Y174A (15).
Mass spectrometry
After transfection with PBF-HA, K1 and TPC1 cells were
lysed in high-salt lysis buffer (50 mM Tris-HCl [pH 7.4], 400
mMNaCl, and 1% vol/vol Igepal CA-630). Proteins interacting
with PBF-HAwere isolated through coimmunoprecipitation us-
ing mouse anti-HA.11 antibody (Covance Research Products)
and separated by SDS-PAGE.Gels were Coomassie-stained, and
each lane was excised and divided into approximately 20 2-mm
segments. After destaining, proteins were reduced, alkylated,
and trypsinized before undergoing HPLC using an acetonitrile
gradient. Samples were then passed straight through an amaZon
ETD ion trap and tandemmass spectrometer (BrukerDaltronics,
Coventry, United Kingdom).
In vitro transcription: translation and glutathione
S-transferase (GST) pulldown assays
TheTNT-coupled reticulocyte lysate system (Promega,Mad-
ison, Wisconsin) was used to express L--[35S]methionine–la-
beled protein from the Src plasmid. GST pulldown assays
were performed to assess binding between GST-tagged PBF
(GST-PBF) and L--[35S]methionine–labeled Src as described
previously (17).
Proximity ligation assay (PLA)
The Duolink In Situ Kit (Olink, Uppsala, Sweden) was used
to detect protein-protein interactions. COS-7 cells were trans-
fected with NIS-MYC and PBF-HA and treated 48 hours later
with pervanadate (100 M) for 15 minutes before fixation. To
assess Src inhibition, cells were treated for 24 hours with either
PP1 (2 M) or an equivalent volume of dimethyl sulfoxide
(vehicle). Fixation, permeabilization, blocking, and primary
antibody (mouse anti-myc and either rabbit anti-HA or rabbit
anti-PBF-pY174) incubations were as performed in the im-
munofluorescent studies. The Duolink In Situ Kit was then
used as per the manufacturer’s instructions. Images were ob-
tained using the Zeiss confocal LSM 510 microscope 40
objective.
Iodide uptake assays
In 24-well plates, TPC1 cells were transfected with either VO
or NIS-HA, and human primary thyroid cultures were trans-
fectedwithVOorPBF-HA (0.5g/well). Cellswere treated at 24
hours posttransfection with either PP1 (2 M) or an equivalent
volume of dimethyl sulfoxide (vehicle), and after a further 24
hours, uptake assays were performed. To demonstrate specific
uptake in the TPC1 cells, the NIS inhibitor sodium perchlorate
was used at 100 M to pretreat control wells for 1 hour before
2878 Smith et al Overcoming PBF Repression of NIS J Clin Endocrinol Metab, July 2013, 98(7):2876–2886
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 05 March 2014. at 08:43 For personal use only. No other uses without permission. . All rights reserved.
the additionof 125I.NaI (final concentration10M)and0.1Ci
of 125I were added directly to the TPC1 cell medium, and 1 M
NaI and 0.05 Ci of 125I were added to the primary thyroid
culture medium. After incubation at 37°C of the TPC1 and pri-
mary thyroid cells for 1 and 3 hours, respectively, medium was
removed, and cells were washed rapidly with Hanks’ balanced
salt solution. Cells were lysed in 2% sodiumdodecyl sulfate, and
the radioactivity of the lysate was counted for 1 minute in a
gamma counter. Results are expressed as picomoles of I per
microgram of protein.
Statistical analyses
Data were analyzed using SigmaStat (SPSS Science Software
Ltd, Birmingham, United Kingdom) and are displayed as
means SEM.All statistical testswere performedwith either the
Student’s t test orMann-Whitney rank sumtest. Significancewas
taken as P  .05.
Results
Mutation of a putative tyrosine sorting signal
results in PBF accumulation at the PM
To identify away to disrupt the inhibitory effect of PBF
on NIS, we initially sought to increase our understanding
of PBF cellular trafficking. Deletion of the C-terminal re-
gion of PBF (residues 149–180) has been shown previ-
ously to increase PM localization (15). Given that PBF
localized within late endosomes with the tetraspanin
CD63 (15), which is commonly associated with clathrin-
dependent endocytosis, we hypothesized that this was due
to the loss of a putative tyrosine-based sorting signal
(YXX) and therefore investigated the functional conse-
quence of the specific mutation of this motif. Substitution
of the critical tyrosine (Y174A) and hydrophobic (F177A)
residues resulted in PBF accumulation at the PM, in con-
trast to the largely vesicular localization of wild-type HA-
tagged PBF (PBF-HA), as demonstrated using immuno-
fluorescent studies (Figure 1A). Cell surface biotinylation
assays provided additional confirmation (Figure 1B).
Thus, discrete abrogation of either the Y174 or F177 res-
idue resulted in increased PM retention, confirming the
presence of a functional YXX internalization motif.
The key tyrosine residue within the sorting signal
(Y174) is phosphorylated
Within the YXX internalizationmotif, the critical ty-
rosine residue at amino acid 174 is strongly predicted to be
a site of phosphorylation (www.phosphosite.org) (21).
Because phosphorylation of this residue would impair its
interaction with clathrin-associated adaptor complexes
(22), such a modification may regulate PBF localization.
To explore this hypothesis we constructed a phospho-spe-
cific antibody to residueY174. Initially, IP of PBF-HAand
subsequent probing with our pY174 antibody confirmed
detection of a specific product at the predicted molecular
mass (Figure 1C) in COS-7 cells, in which we have previ-
ously examined PBF function, as well as papillary thyroid
carcinomaK1cells. TheY174Amutant, however,wasnot
detected by the phospho-specific antibody. Immunofluo-
rescent staining of PBF-HA–transfected COS-7 cells with
our pY174 antibody revealed coincident expression of ty-
rosine-phosphorylated PBF and total exogenous PBF, par-
ticularly within the PM (Figure 1D). Further, in Y174A-
transfected cells, the pY174 antibody detected endogenous
phospho-PBF at the PM but not the Y174A mutant, con-
firming specificity of the antibody (Figure 1D). Phospho-
specific detection of pY174was further established through
experiments performed in the presence and absence of the
protein tyrosinephosphatase inhibitorpervanadate (seeSup-
plemental Figure 1 published on The Endocrine Society’s
Journals Online web site at http://jcem.endojournals.org.).
PBF colocalizes with NIS in numerous cell lines
PBF is a transmembrane protein that shuttles NIS be-
tween the PM and the cytoplasm, with profound impli-
cations for ablative radioiodine uptake during thyroid
cancer treatment (15). We have previously demonstrated
PBF colocalization with NIS in COS-7 and FRTL-5 rat
thyroid cells, predominantly within intracellular vesicles
of the late endosome phenotype (15). We now extend this
observation to 9 commonly used cancer cell lines of breast
(T47D), prostate (VCaP and LNCaP), colorectal
(HCT116), ovarian (A2780), and osteosarcoma (Saos-2)
lineages, as well as K1, TPC1, and SW1736 thyroid cells.
Relative endogenous expression of PBFwas characterized
in a number of these cell lines as determined by Western
analysis (Supplemental Figure 2). MYC-tagged NIS was
initially transfected alone and appeared to be correctly
targeted to the PM in each of these cell lines (Figure 2A).
Variable amounts of intracellular expression were also
observed. After cotransfection, PBF-HA showed vesicular
colocalization with NIS-MYC in each of these cell lines
(Figure 2B), with varying degrees of PM colocalization, as
we have described previously forCOS-7 cells (15).On this
basis, we consider that PBF colocalization with NIS is
broadly universal.
Given that PBF is phosphorylated at Y174 and colo-
calizes with NIS, we next determined through confocal
microscopywhether the pY174 formof PBF localizeswith
NIS in a subset of this collection of cell lines. Compared
with total PBF immunofluorescence (Figure 2B) and con-
sistent with the images in COS-7 cells (Figure 1D), PBF
pY174 appeared to be distributed more readily at the PM
in these cells (Figure 2C). Specific colocalization of NIS-
MYCand PBF pY174 (magenta) was evident, bothwithin
intracellular vesicles and at the PM (Figure 2C). In con-
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trast, significant intracellular colocalization was not evi-
dent between NIS-MYC and the Y174A mutant (Supple-
mental Figure 3).
PBF interaction with the tyrosine kinase Src
Because abrogation of Y174 altered PBF subcellular lo-
calization (Figure 1A) and phospho-PBF colocalized with
NIS (Figure 2C), we studied the pY174 modification in fur-
ther detail and examined whether this might regulate the
ability of PBF to alter NIS localization. To screen for a ty-
rosinekinasecapableofphosphorylatingPBF,weperformed
extensive tandem mass spectrometry
studies in different cell lines. These
studies identified the proto-oncogene
tyrosine protein kinase Src as a puta-
tive binding partner of PBF (peptide
match with a score of 26.8 and se-
quence coverageof6.5%).On this ba-
sis, we performed GST pulldown as-
says in which GST-tagged PBF pulled
back L--[35S]methionine–labeled Src
(Figure 3A). We therefore proceeded
to coimmunoprecipitation assays in
HeLa cells to examine putative bind-
ing in a cellular context. Coimmuno-
precipitated Src was detected after the
IP of PBF-HA with a HA antibody
(Figure 3B). In the reciprocal assay, IP
of Src and the subsequent detection of
coimmunoprecipitated PBF-HA fur-
ther established an in vitro interaction
between PBF and Src (Figure 3B).
The subcellular localization of
this interaction in vitro was assessed
through immunofluorescent analy-
sis of HeLa cells cotransfected with
PBF-HA and Src. Colocalization of
PBF-HA and Src was observed pre-
dominantly at the PM and in the pe-
rinuclear region (Figure 3C). Given
the analogous staining pattern of
pY174 (Figure 2B), these data fur-
ther suggest that Src binds and phos-
phorylates PBF and that this occurs
either at the PM, in the perinuclear
region, or both.
Effect of manipulating Src on
pY174
To determine whether Src is in-
deed capable of phosphorylating
PBF, we transfected HeLa cells with
PBF-HA and Src and examined
pY174 expression. Western blotting confirmed detection
of pY174 inHeLa cells transfected with PBF-HA that was
absent in Y174A-transfected cells (Figure 4A). Subse-
quently, transient overexpression of Src resulted in signif-
icantly increased phosphorylation of PBF-HA compared
with VO controls (Figure 4B). To determine whether this
was reversible, we appraised the Src kinase inhibitor PP1,
along with a negative control compound PP3, which
shares a structure similar to that of PP1 but does not affect
Src kinase activity.Comparedwith vehicle, PP1 resulted in
Figure 1. PBF is phosphorylated at tyrosine residue 174, which is critical for endocytosis. A,
Subcellular localization of HA-tagged wild-type and mutant PBF was determined by
immunofluorescent staining using an anti-HA antibody after transfection into COS-7 cells. Both
Y174A and F177A accumulated at the plasma membrane, in contrast to PBF-HA, which was
localized mainly in intracellular vesicles. Bars, 20 m. B, Representative cell surface biotinylation
assay demonstrating increased plasma membrane expression of the Y174A and F177A mutants
compared with that for PBF-HA. PBF is a glycoprotein that is typically detected with bands of
between 25 and 30 kDa. C, IP of PBF-HA and subsequent probing with a phospho-specific
pY174 antibody in COS-7 and K1 cell lysate, confirming detection of a specific product at the
predicted molecular mass but not the Y174A mutant. D, Immunofluorescent studies in COS-7
cells transfected with PBF-HA and Y174A and probed with our phospho-tyrosine antibody and
an anti-HA antibody. Coincident expression (yellow) was apparent for tyrosine-phosphorylated
PBF (red) and exogenous PBF (green) for PBF-HA but not the Y174A mutant. Bars, 20 m.
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a potent repression of Src-induced pY174 expression. In
contrast, parallel treatment with PP3 failed to alter Src-
induced pY174 phosphorylation (Figure 4C). Suppres-
sion of pY174 by PP1 was also observed without Src
overexpression in HeLa cells transfected with PBF-HA
(Figure 4D).
Activated Src has been demonstrated in a number of
thyroid carcinoma cell lines (23), and we assessed PBF
phosphorylation in the papillary carcinoma thyroid lines
TPC1 and K1. After transfection of PBF-HA in TPC1 and
K1cell lines, pY174wasbothdetectedandhighly sensitive
to PP1 treatment (Figure 4D). Notably, endogenous
pY174 expression could also be detected and inhibited by
PP1 treatment in TPC1 and K1 thyroid cell lines (Figure
4D). Given that PBF function has been reported to be
central to iodide uptake and thyroid hormone efflux in
thyroid cells (15, 17), we further extended these obser-
vations to human primary thyroid cultures. Despite the
reported heterogeneity of such cultures, multiple prep-
arations demonstrated endogenous PBF pY174 phos-
phorylation, which was significantly inhibited by PP1
(81.1  7.8% reduction, P  .001, n 	 5) (Figure 4E).
Figure 2. PBF and NIS colocalization in multiple cell lines. A, Confocal immunofluorescence microscopy demonstrating MYC-tagged NIS (green)
localization in COS-7, HCT116, VCaP, Saos-2, SW1736, TPC1, K1, LNCaP, T47D, and A2780 cells. Bars, 20 m. B, Confocal microscopy
demonstrating PBF-HA (red) and NIS-MYC (green) expression, detected using anti-HA and anti-MYC antibodies, respectively, with specific
colocalization (yellow) observed predominantly within intracellular vesicles. Bars, 20 m. C, Confocal images of PBF pY174 (red) and NIS-MYC
(blue) localization, determined using anti-pY174 and anti-MYC antibodies, respectively, in TPC1, K1, LNCaP, T47D, and A2780 cells. Specific
colocalization is represented in magenta. Bars, 20 m.
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These data demonstrate that Src overexpression induces
pY174andSrc inhibition suppressespY174. Interestingly,
endogenous Src-mediated pY174 is observed in human
primary thyroid cultures, suggesting this may be a mech-
anism of PBF regulation apparent in normal thyroid cells.
The Y174 site is important for NIS interaction
Because PBF binds NIS and alters its subcellular local-
ization (15), we next examined the relevance of the Y174
site to NIS interaction. Coimmunoprecipitation studies in
COS-7 cells revealed that alanine substitution at the Y174
residue almost completely abrogated PBF binding to NIS
(Figure 5A). The interaction between NIS and PBF-HA
was also observed using the PLA. Once again, the Y174A
mutant demonstrated a very signifi-
cantly reduced ability to bind NIS.
Thus, the Y174 residue is critical for
the interaction between PBF and
NIS. Given the observed colocaliza-
tion between PBF-pY174 and NIS,
we then assessed whether the phos-
phorylated form of PBF could bind
NIS. An interaction was detected be-
tween pY174 and NIS by coimmu-
noprecipitation after the transfec-
tion of PBF-HA and NIS-MYC in
HeLa cells (Figure 5B). Binding be-
tween pY174 andNISwas also dem-
onstrated in COS-7 cells using the
PLA (Figure 5B). We then used the
PLA techniquewithin this context to
assess the effect of Src inhibition on
the interaction between PBF-pY174
andNIS. Sites of interaction between
PBF-pY174andNISwereonce again
observed, with the most intense ar-
eas of staining apparent at the PM
(Figure 5C). After PP1 treatment,
there appeared to be a reduction in
both the overall amount of binding
and in the level of interaction at the
PM (Figure 5C). These observations
suggest that the phosphorylated
form of PBF can bind NIS, at least
partly at the PM, and that inhibition
of Src with PP1 can diminish this
interaction.
Treatment with PP1 overcomes
PBF repression of iodide uptake
PBF has been shown to potently
repress iodide uptake in vitro and in
vivo (15, 16). Oncogenic expression
would therefore be hypothesized to result in inappropriate
retention of NIS away from the PM and hence reduced
efficacy of radioiodine ablation therapy. Given the impor-
tance of Y174 to PBF:NIS binding and colocalization, we
finally determined the influence of modulating PBF phos-
phorylation status on iodide uptake. TPC1 cells demon-
strated no NIS-specific endogenous iodide uptake com-
pared with that for sodium perchlorate-treated controls
(Figure 5D). Transfection with NIS resulted in a signifi-
cant increase in NIS-mediated uptake (1.16  0.04 vs
0.17 0.01 pmol of I per g of protein compared with
values for VO treatment, P .001, n	 8) (Figure 5D). In
cells containing exogenous NIS, uptake could be signifi-
Figure 3. Src interaction and colocalization with PBF. A, GST pulldown assay demonstrating in
vitro binding between GST-tagged PBF (GST-PBF) and L--[35S]methionine–labeled Src. GST-only
and 10% input lanes are shown for comparison. B, After IP of PBF-HA with anti-HA antibody
from HeLa cell lysate, the coimmunoprecipitation of exogenous Src was determined by Western
blotting and probing with anti-Src antibody. The reciprocal assay is also shown. WB, Western
blot. C, Epifluorescent (top panel) and confocal (bottom panel) images of PBF-HA (green) and Src
(red) localization, determined using anti-HA and anti-Src antibodies, respectively, with specific
colocalization (yellow) in HeLa cells. Bars, 20 m.
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cantly enhanced through PP1 treatment (1.93  0.19 vs
1.16 0.04 pmol of I per g of protein compared with
values for vehicle treatment, P	 .007, n	 8) (Figure 5D).
Treatment with PP1 did not elicit an increase in endoge-
nous iodide uptake, whichmay suggest that Src inhibition
cannot stimulate NIS expression but
instead induces NIS activity in a
posttranslational manner.
Treatment of humanprimary thy-
roid cultures with PP1 (2M) for 24
hours also confirmedno effect on en-
dogenous NIS protein expression
levels (0.960.07-fold change com-
pared with that for vehicle treat-
ment, P 	 .656, n 	 3) (Figure 5E).
As shown previously in human pri-
mary thyroid cells (14), PBF-HA
overexpression was associated with
a significant decrease in 125I uptake
(47.2  9.2% reduction, P 	 .004,
n 	 6) (Figure 5F). However, treat-
ment of PBF-HA–transfected cul-
tures for 24 hours with 2 M PP1
entirely rescued iodide uptake (1.82 
0.42-fold increase compared with
PBF-HA and vehicle treatment, P 	
.048, n	 6) (Figure 5F). This result-
ing uptake in PBF-HA-transfected
cells treated with PP1was not signif-
icantly different from that for un-
transfected, vehicle-treated cells
(0.96  0.2-fold, P 	 .848, n 	 6)
(Figure 5F). Hence, PP1 treatment
completely abrogated the repression
of iodide uptake by PBF. These data
suggest, therefore, that overcoming
PBF repression of NIS may be possi-
ble by targeting its phosphorylation
by Src.
Discussion
For the first time, these data identify
the proto-oncogene PBF as a phos-
phoprotein and highlight the impor-
tance of the tyrosine residue Y174 in
both the endocytosis of PBF and its
interaction with NIS. Critically, we
have associated the Src tyrosine ki-
nase with phosphorylation of PBF
Y174 and established that, through
reduction of pY174 levels, PBF re-
pression of iodide uptake can be ameliorated. Further-
more, the effect of PBFoverexpression onNIS localization
appears to be ubiquitous, suggesting that therapeutic tar-
geting of PBF will be required for efficacious radioiodine
uptake in tumors with high PBF expression. This would
Figure 4. Src regulates Y174 phosphorylation. A, Western analysis of pY174 in lysate from HeLa
cells transfected with PBF-HA and Y174A. PBF is a glycoprotein that is typically detected with
bands of between 25 and 30 kDa. B, HeLa cells transfected with PBF-HA and Src demonstrated
significantly increased pY174 compared with PBF-HA and VO controls. C, Treatment of HeLa cells
transfected with PBF-HA and Src with 2 M Src kinase inhibitor PP1 for 30 minutes elicited
potent repression of pY174 expression compared with that for vehicle only treatment (Veh),
whereas the related negative control compound PP3 (2 M) failed to alter pY174
phosphorylation. D, PP1 treatment (2 M for 30 minutes) resulted in the inhibition of pY174 in
HeLa cells and the papillary carcinoma thyroid lines TPC1 and K1 transfected with PBF-HA. Right-
hand panel, endogenous pY174 expression in TPC1 and K1 cells observed with pervanadate (PV)
treatment and inhibited by PP1 treatment (2 M for 24 hours). E, Endogenous pY174 in human
primary thyroid cultures treated with 2 M PP1 for 30 minutes (each treatment was performed in
duplicate in each of n 	 5 preparations). ***, P  .001.
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apply equally to tumors with endogenous NIS expression
such as thyroid or breast cancer, to tumors in which NIS
expression may be induced, such as poorly differentiated
or anaplastic thyroid cancer, and to tumors in which NIS
gene therapy may be administered, such as prostate or
ovarian cancer.
Although radioiodine is generally considered to be a
safe treatmentmodality, risks of a secondmalignancy and
other adverse effects indicate that administered radiation
doses should be minimized, the gold standard being suc-
cessful remnant ablation or treatment of metastatic dis-
ease with minimal doses. We propose that targeting PBF
Figure 5. Y174 is critical for NIS binding, and Src inhibition overcomes PBF repression of iodide uptake. A, Coimmunoprecipitation assay in COS-7
cells. After IP of NIS-MYC with a mouse anti-Myc antibody, PBF-HA was detected using mouse anti-HA antibody. Y174A substitution diminished
interaction with NIS. IgG, light chain immunoglobulin. WB, Western blot. Bottom panel, representative images of a PLA showing an interaction
between NIS-MYC and PBF-HA in COS-7 cells using anti-MYC and anti-HA antibodies. Specific interactions are visualized with a red fluorescent
spot. B, Similarly, after IP of NIS-MYC from HeLa cell lysate, an interaction with PBF-pY174 was detected using the pY174 antibody. Bottom panel,
representative images of a PLA showing an interaction between NIS-MYC and PBF-pY174 in COS-7 cells using anti-MYC and anti-pY174
antibodies. C, Protein-protein interactions between PBF-pY174 and NIS-MYC were observed particularly at the PM using the PLA technique with
vehicle (Veh) treatment (top panel). Reduced binding was evident after PP1 treatment (2 M) for 24 hours in the bottom representative panel. D,
Iodide uptake in TPC1 cells transfected with VO or NIS and treated with either vehicle or PP1 (2 M) for 24 hours. NIS-mediated iodide uptake was
demonstrated through the use of controls treated with 100 M sodium perchlorate (NaClO4) for 1 hour before addition of
125I. E, Western blot
analysis of endogenous NIS expression in human primary thyroid cultures treated for 24 hours with either vehicle or PP1 (2 M). F, Human primary
thyroid cells were transfected with VO or PBF-HA, and 48 hours later iodide uptake assays were performed. A significant reduction in iodide
uptake was observed with PBF overexpression. Cultures treated with PP1 (2 M) for 24 hours before the addition of 125I demonstrated uptake
comparable with that of VO-transfected cells. n 	 6 cultures. ns, not significant. ***, P  .001; **, P  .01; *, P  .05.
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phosphorylationmay in the future satisfy the dual goals of
driving 131I efficacy with minimized radiation exposure.
The interaction of PBF with Src was initially identified
by mass spectrometry and subsequently confirmed
through GST pulldown assays and both forward and re-
verse coimmunoprecipitation assays. Although Src binds
PBF andoverexpression of Src is associatedwith increased
Y174 phosphorylation, it is possible that the influence of
Src on PBF is indirect and that Src interaction fulfills some
other as yet unknown function. It is also conceivable that
kinases that lie downstream of Src may be more specific
targets to ameliorate PBF phosphorylation. Future studies
will thus seek to identify the regions of PBF and Src nec-
essary for interaction andwill elucidate whether Src bind-
ing results directly in PBF phosphorylation.
Although there was broad colocalization of PBF with
NIS in a panel of 10 distinct cell lines, clearly only a pro-
portion of cytoplasmic and membranous protein binds
and colocalizes at any particular moment. Notably, a di-
rect interactionbetweenNISand thephosphorylated form
of PBF was detected by 2 different methodologies and in
both HeLa and COS-7 cells. However, we are unable at
present to answer the question of precisely howphosphor-
ylation of Y174 affects PBF localization, which will form
the basis of future studies. PP1 inhibition of pY174 was
potent and reproducible in untransformed human pri-
mary thyroid cells. This physiologically relevant model
also revealed that PP1was able to rescue PBF inhibition of
radioiodine uptake. It is possible that these data underes-
timate the potency of PBF repression of NIS function,
given that transfection efficiency for these primary cells, as
we have previously reported (14), is in the order of 45%
to 95%.
Because our recent data show that PBF also modulates
the function of the monocarboxylate transporter 8 (17),
which regulates thyroid hormone efflux from the thyroid
gland (24, 25), our collective findings suggest a funda-
mental role for PBF in normal thyroid physiology, albeit
one that appears to be dysregulated in neoplasia. The pre-
cise contribution of Y174 phosphorylation to the regula-
tion of iodide uptake and thyroid hormone efflux in
untransformed thyroid cells, however, remains to be
discerned.
Overall, we propose tyrosine phosphorylation of PBF
as a novel therapeutic target to overcome inhibition of
radioiodineuptake. Further studieswill nowbe conducted
to seek to elucidate the precise mechanisms that regulate
the interaction between PBF and NIS and to identify the
most effective and specific inhibitor of PBF Y174
phosphorylation.
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